[Treatment of the Wiskott-Aldrich syndrome by a graft of allogeneic bone marrow].
We herein describe the first French case of successful bone marrow transplantation (BMT) in a patient with the Wiskott-Aldrich syndrome. Although the patient required hospitalization for a total of one year during his first 4 years of life for bleeding, eczema, protracted diarrhea and multiple infections, the bone marrow transplantation has permitted a complete and stable correction of the thrombocytopenia, the eczema and the immunodeficiency. The patient was prepared by a total body irradiation (850 rads) with a partial lung shielding and anti-lymphocyte globulins. The BMT was immediately followed by a severe but transient herpetic infection and acute graft versus host reaction (grade II) which resolved after steroid therapy. The thrombocytopenia disappeared 3 months after the BMT. The infections and the eczema did not reappear. Immune functions are entirely normal and all blood cells have been shown to be of donor origin (the sister of the recipient). The boy is growing normally and is doing well 3 1/2 years thereafter. He only suffered from bilateral cataracts secondary to the irradiation requiring lens extraction. One can now expect a success rate of 75% in bone marrow transplantation in patients with Wiskott-Aldrich syndrome as evaluated from a world review. In contrast, symptomatic treatment of the disease leads to a mean survival of 7 years, survival rarely exceeding 18 years.
D016026:Bone Marrow Transplantation; D006087:Graft vs Host Reaction; D006801:Humans; D007223:Infant; D007239:Infections / Q000209:etiology; D008297:Male; D011183:Postoperative Complications; D013997:Time Factors; D014923:Wiskott-Aldrich Syndrome / Q000276:immunology / Q000601:surgery*
Traitement du syndrome de Wiskott-Aldrich par greffe de moelle allogénique.